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Abstract
Metallo-b-lactamase (MBL) producers have been reported among the various Acinetobacter species worldwide. In this study, the
epidemiology and molecular characteristics of carbapenemase-encoding genes and mobile elements were studied to analyse the regional
dissemination of MBL genes in Acinetobacter species. From January 2001 to December 2006, 48 Acinetobacter isolates harbouring MBL
genes identified from five hospitals in Kyoto and Shiga Prefecture, Japan were collected and analysed. The partial rpoB gene or the
16S-23S ribosomal RNA intergenic spacer region was sequenced to obtain a species-level identification. Molecular typing using pulsed-
field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) was performed. Twenty-five Acinetobacter pittii isolates were
divided into eight PFGE types and five sequence types (STs) using MLST. Nine Acinetobacter bereziniae isolates belonged to five PFGE
types. Five Acinetobacter nosocomialis isolates were divided into two PFGE types and two STs. Three unclassified Acinetobacter species
isolates were divided into two PFGE types. Eighteen of the 25 A. pittii isolates belonged to ST119 and were identified from four
hospitals. The blaIMP-19 gene was detected in 41 of 48 isolates, including all of the A. pittii ST119 isolates. The blaIMP-1 and blaIMP-11 genes
were detected in four and three isolates, respectively. The MBL genes were all embedded within a class 1 integron as a gene cassette
array: blaIMP-19-aac(6¢)-31-blaOXA-21-aadA1, catB8-like/aacA4-blaIMP-1 and blaIMP-11. This study is the first report demonstrating the regional
dissemination of MBL-producing Acinetobacter species. A. pittii ST119 harbouring blaIMP-19 was widely spread throughout the Kyoto-Shiga
region.
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Introduction
Over the past two decades, the number of carbapenem-resis-
tant Acinetobacter species isolates has dramatically increased,
and these organisms have been disseminated worldwide.
Metallo-b-lactamases (MBLs) and carbapenem-hydrolysing
class D b-lactamases (CHDLs) are common contributors to
carbapenem resistance [1]. MBL genes are typically embedded
in integrons that accumulate antimicrobial resistance gene
cassettes that are associated with the intra- and interspecies
transfer of these resistance genes. Insertion sequence (IS)
elements, another type of mobile genetic element, may pro-
vide promoters that induce overexpression and play a role in
the acquisition of CHDL genes [1].
Acinetobacter baumannii strains, especially those belonging to
worldwide lineages, such as European clone I, II and III, have
been reported to show carbapenem non-susceptibility, which
is primarily due to CHDLs [2,3]. IMP-, VIM- and NDM-type
MBL genes have been detected among A. baumannii [4]. In
addition, MBL genes have also been detected among various
Acinetobacter species other than A. baumannii, such as: blaIMP-1,
-4, and -8 and blaVIM-2 among Acinetobacter pittii (formerly Acineto-
bacter genomic species 3); blaIMP-1, and -4 and blaVIM-11 among
Acinetobacter nosocomialis (formerly Acinetobacter genomic spe-
cies 13TU); blaIMP-1, blaVIM-2 and blaSIM-1 among Acinetobacter
bereziniae (formerly Acinetobacter genomic species 10); blaVIM-4
among Acinetobacter genomic species 16; blaIMP-1 among Acineto-
bacter radioresistens; and blaVIM-11 among Acinetobacter junii [5–9].
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In a previous study, we identified the dissemination of
blaIMP-19, which is located in a class 1 integron in various Aci-
netobacter species, including A. baumannii, A. pittii, Acinetobac-
ter johnsonii and A. junii [10]. However, this study was only
performed at a single institute, and the regional dissemina-
tion of MBL genes among Acinetobacter species has not been
studied extensively. Therefore, the aim of this study was to
analyse the regional epidemiology of MBL genes and their
genetic environments among Acinetobacter species.
Materials and Methods
Bacterial isolates and MBL screening
From January 2001 to December 2006, a total of 1713 Aci-
netobacter species clinical isolates were identified from five
hospitals, including three teaching university hospitals (A, B
and E) and two city hospitals (C and D) in Kyoto and Shiga
Prefecture, Japan. Three hospitals (A, B and C) were located
in Kyoto, and two hospitals (D and E) were located in Shiga.
The isolates were primarily identified as Acinetobacter species
using the VITEK2 system (Sysmex-bioMe´rieux, Marcy l’Etoile,
France) or the MicroScan system (Siemens Healthcare Diag-
nostics, Tokyo, Japan) in each hospital. Eighty-two of 1713
isolates with resistance to carbapenems or ceftazidime were
detected using an automated system through phenotypic
MBL screening. A phenotypic MBL screening test was per-
formed using three disks (two Kirby-Bauer disks containing
30 lg of ceftazidime and one disk containing 3 mg of sodium
mercaptoacetic acid (Eiken Chemical, Tokyo, Japan)), as pre-
viously described [11]. A ‡5 mm difference in the inhibition
zone between the disks was considered a positive result for
the detection of MBL. Fifty-four MBL-positive isolates of Aci-
netobacter were sent to Kyoto University Hospital for further
analysis. Only one MBL-positive isolate per patient was
included in this study. PCR screening was performed for the
MBL genes (blaIMP, blaVIM and blaNDM-1) [10]. A total of 48 of
the 54 Acinetobacter isolates were positive for MBL genes
and were included in this study.
Species-level identification
Species identification was performed through sequencing of
the partial rpoB gene (zone 1 between positions 2916 and
3267, 352 bp), as previously described [12,13]. The nucleo-
tide sequence homology was searched using the BLAST pro-
gram (http://www.ncbi.nlm.nih.gov/BLAST). For isolates of
the non-Acinetobacter calcoaceticus-Acinetobacter baumannii
(ACB) complex, the sequences were compared with the ref-
erence sequences of Acinetobacter strains using the neigh-
bour-joining method of the CLUSTAL X program [13]. The
intergenic spacer region of 16S-23S ribosomal RNA was
sequenced to identify the ACB complex [14].
Molecular typing
Molecular typing was performed using pulsed-field gel elec-
trophoresis (PFGE) with the GenePath system (Bio-Rad,
Tokyo, Japan) and the restriction enzyme ApaI (New England
BioLabs, Tokyo, Japan), as previously described [15]. The
pattern analysis was conducted using GelCompar II v.4.062
software (Applied Maths, Sint-Martens-Latem, Belgium) with
the unweighted-pair group method based on Dice coeffi-
cients and a cut-off of 80% similarity. Multilocus sequence
typing (MLST) was also performed on the ACB complex
using the Pasteur Institute scheme, and the results were
analysed according to the Institut Pasteur MLST Database
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abau-
mannii.html) [16].
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined using the broth
microdilution method with commercially manufactured plates
(Eiken Chemical) according to the 2012 CLSI guidelines and
breakpoint criteria [17,18].
PCR amplification of carbapenemase-encoding genes, in-
tegrase genes and ISs
PCR screening was performed for the carbapenemase-encod-
ing genes and mobile genetic elements, including the CHDL
genes (blaOXA-23-like, blaOXA-24-like, blaOXA-51-like and blaOXA-
58-like), integrase genes (intI1, intI2 and intI3) and IS element
genes (ISAba1, ISAba2 and ISAba3), in addition to MBL genes,
as previously described [10].
Analysis of a class 1 integron carrying MBL genes and the
genetic environment of CHDL genes
For the detection of class 1 integron gene cassettes, PCR
amplification (integron PCR) was performed with primers
directed toward the 5¢-conserved segments (CSs) and 3¢-CS
using PrimeSTARTM HS DNA polymerase (TaKaRa Bio,
Otsu, Japan) (Fig. 1). The PCR procedures, cloning and
sequence analysis of class 1 integron cassettes have been
previously described [10]. For analysis of class 1 integrons
carrying blaIMP-19, cloning and sequencing were conducted
for five clinical isolates and other strains harbouring blaIMP-19
using PCR mapping with the newly designed primer sets
(Fig. 1) [19]. Cloning and sequencing were also performed to
identify the genetic arrays of class 1 integrons carrying
blaIMP-1 and blaIMP-11. To determine the genetic structures of
the regions that flank the CHDL genes, a PCR analysis was
performed using a series of previously described primers
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[20]. The primers used in the analysis of the genetic environ-
ment are shown in Table S1.
Nucleotide sequence accession numbers
The nucleotide sequences of the integron gene cassettes that
are newly reported in this paper have been submitted to the
DNA Data Bank of Japan (DDBJ) and have been assigned the
accession numbers AB713931, AB713932, AB713933,
AB713952, AB713953 and AB713954.
Results and Discussion
Bacterial isolates and species identification
For this study, 48 clinical isolates of the Acinetobacter species
that harboured the MBL gene were identified in the Kyoto-Shi-
ga region. Twenty-five isolates were identified as A. pittii, nine
isolates were identified as A. bereziniae, five isolates were iden-
tified as A. nosocomialis, and three isolates were unclassified
Acinetobacter species. Single isolates of A. baumannii, Acinetobac-
ter guillouiae (formerly Acinetobacter genomic species 11), Aci-
netobacter genomic species 15TU, Acinetobacter genomic
species 16, A. junii and Acinetobacter ursingii were also identi-
fied. Fig. 2 illustrates the phylogenetic relationships between
non-ACB complex isolates and Acinetobacter reference strains.
A total of three Acinetobacter species isolates exhibited c. 96%
identity to the rpoB gene in Acinetobacter gyllenbergii and
belonged to the same species with high bootstrap values in the
phylogenetic tree. However, these three isolates had a low
bootstrap value (49.2%) for the corresponding branch of
A. gyllenbergii. Therefore, we defined these isolates as ‘unclassi-
fied’ Acinetobacter species. The presence of unclassified species
has been previously reported for the identification of Acineto-
bacter species using the partial rpoB gene sequence [13]. A. pittii
isolates were identified from four hospitals (A, B, D and E),
A. bereziniae isolates were identified from three hospitals (A, B
and C), A. nosocomialis isolates were identified from three hos-
pitals (A, B and D) and unclassified Acinetobacter species were
identified from two hospitals (A and B) (Table 1). The origins
of A. pittii, A. bereziniae, A. nosocomialis and unclassified Acineto-
bacter species isolates are shown in Fig. 3. The origins of other
isolates were obtained as follows: one A. baumannii (strain
A12) was recovered from a nasopharyngeal swab; one A. guillo-
uiae isolate (A13) was recovered from bile; single isolates of
A. genomic species 16 (A5) and A. genomic species 15TU (A9)
were recovered from ascites; a single A. junii isolate (E7) was
recovered from sputum; and a single A. ursingii isolate (A7) was
recovered from blood.
The genus Acinetobacter currently comprises 27 validly
named species and several other genomic species with provi-
sional designations [21–23]. Using PCR-based species-level
identification [12,14], we identified Acinetobacter species har-
bouring MBL genes that had not previously been reported
(e.g. A. guillouiae, genomic species 15TU and A. ursingii).
These identification and molecular typing methods are neces-
sary for developing a detailed epidemiology of MBL genes
among non-A. baumannii Acinetobacter species.
Molecular typing
Fig. 3 shows the results of molecular typing using PFGE and
MLST. The 25 A. pittii isolates were divided into eight PFGE
types and five sequence types (STs) using MLST (ST63, ST64,
ST93, ST119 and ST121) (Fig. 3a). ST119 was identified in
closely related A. pittii isolates from four hospitals (A, B, D
and E) (Table 1). The A. pittii non-ST119 isolates were identi-
fied from two hospitals (A and B), but only one clonal PFGE
type was identified in the ST63 isolates. The other isolates
were sporadically identified (Fig. 3a). The nine A. bereziniae
isolates were primarily identified from two hospitals (A and
B) and could be divided into five PFGE types; the PFGE
(a)
(b)
(c)
catB8-like/aacA45′-CS
Pint1 Sint4
bla5′-CS IMP-11 3′-CS
Pint2Pint1
blaIMP-19 aac(6′)-315′-CS
Sint2Sint1Pint1
Pmap1 Pmap2 Pmap3
blaIMP-1 3′-CS
1 kb
Pint2
aadA1blaOXA-21 3′CS
Sint3 Pint2
Pmap5Pmap4 Pmap6
FIG. 1. Schematic representation of the class 1 integron gene cassettes obtained from the Acinetobacter isolates. The black circles indicate the
attC recombination sites. The large white arrows indicate the integron gene cassettes. The small arrows indicate the primers for PCR amplifica-
tion (mapping) and/or sequencing. The arrowheads indicate the primers designed for sequencing in this study.
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FIG. 2. Neighbour-joining tree based on the partial rpoB gene (zone 1) sequence from isolates containing the non-ACB complex and reference
strains of the Acinetobacter species. The cluster analysis was conducted using the CLUSTAL X program. The GenBank accession numbers
are shown in parentheses. The numbers at the branch points indicate the bootstrap values (%, based on 1000 resamplings). Bar, 1% sequence
divergence.
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analysis revealed that five of the nine isolates were closely
related (Fig. 3b). The five A. nosocomialis isolates were
divided into two PFGE types and two STs (ST68 and ST71)
(Fig. 3c). The three unclassified Acinetobacter species isolates
were divided into two PFGE types (Fig. 3d). PFGE was not
performed on the other Acinetobacter species because only
one isolate of each species was positive for the MBL gene.
An A. baumannii isolate belonging to ST120 was not related
to European clones I, II or III.
The molecular epidemiologies of the Acinetobacter isolates
harbouring MBL genes are lacking. Although the molecular
epidemiologies of A. pittii are currently insufficient for com-
parison with A. baumannii, the Pasteur Institute MLST scheme
might be more applicable than the Bartual scheme for the
number of sequence types submitted (http://pubmlst.org/
abaumannii). Thus, we conducted MLST using the Pasteur
Institute scheme.
Antimicrobial susceptibility
The antimicrobial susceptibility profiles are shown in Table 2.
None of the isolates were susceptible to imipenem. How-
ever, three isolates of A. pittii ST119 and one isolate of
A. baumannii were susceptible to meropenem. Most of the
isolates were susceptible to minocycline, colistin and ampicil-
lin-sulbactam. However, ampicillin-sulbactam and colistin
exhibited lower susceptibility rates against A. bereziniae,
A. nosocomialis and unclassified Acinetobacter species than
against other Acinetobacter isolates. In particular, all three of
the unclassified Acinetobacter species isolates were resistant
to colistin. The aminoglycosides had lower susceptibility
rates against A. pittii non-ST119 and A. nosocomialis species
than against other Acinetobacter isolates.
Carbapenemase-encoding genes and the genetic environ-
ment
All of the isolates harboured the class 1 integrase gene (intI1).
Table 2 outlines the distribution of MBL genes among the
Acinetobacter species. The blaIMP-19 gene was predominantly
detected in Acinetobacter isolates, including 23 isolates of
A. pittii (all 18 isolates of ST119) and all isolates of A. bereziniae,
A. nosocomialis, A. baumannii, A. guillouiae, genomic species 16
and A. junii. The blaIMP-1 gene was detected in four isolates
(A. pittii, unclassified Acinetobacter species, genomic species
15TU and A. ursingii) and blaIMP-11 was detected in three
isolates (A. pittii and two unclassified Acinetobacter species
isolates).
CHDL genes primarily contribute to carbapenem non-sus-
ceptibility among Acinetobacter species [2,24]. Even in Japan, a
recent study showed that 94.5% of the carbapenem-resistant
Acinetobacter isolates harboured CHDL genes, and only one
A. pittii isolate harboured an IMP-type MBL gene [25]. How-
ever, in another study conducted in Asia, A. pittii was reported
to harbour MBL genes, including blaIMP-1, -4, and -8 and blaVIM-2
[6,7,9].
All of the MBL genes detected in this study were embed-
ded in a class 1 integron. The blaIMP-19 gene was identified in
a gene cassette array of blaIMP-19-aac(6¢)-31-blaOXA-21-aadA1,
the blaIMP-1 gene was in an array of catB8-like/aacA4-blaIMP-1,
and blaIMP-11 was the only component of another gene cas-
sette array (Fig. 1). The same class 1 integron carrying blaIMP-
19 was detected in various Acinetobacter species. While this
finding was reported in our previous study, the identification
of this integron in A. nosocomialis, A. bereziniae and A. guillo-
uiae was a recent discovery. These findings provide strong
evidence for the inter- and intraspecies dissemination of this
class 1 integron among Acinetobacter species. In contrast, no
evidence of the intraspecies dissemination of a class 1 integ-
ron carrying blaIMP-1 and blaIMP-11 was demonstrated,
although the regional spread and interspecies dissemination
of these two MBL genes was detected.
One isolate of A. baumannii ST120 harboured blaOXA-51-like
and ISAba2 in addition to blaIMP-19, but ISAba2 was not identi-
fied up- or downstream of blaOXA-51-like. ISAba3 flanked both
sides of the blaOXA-58 gene, which was detected in the single
isolate of A. pittii ST93 harbouring blaIMP-1 and three isolates
(one isolate of A. pittii ST63 and two isolates of unclassified
Acinetobacter species) harbouring blaIMP-11 (Fig. 3). Other
CHDL genes were not detected in the isolates included in
TABLE 1. Numbers of isolated Acinetobacter strains
2001 2002 2003 2004 2005 2006 Total Hospitalsc
A. pittii (ST119) 1 5 7 3 2 18 A, B, D, E
A. pittii (non-ST119a) 4 2 1 7 A, B
A. bereziniae 1 3 4 1 9 A, B, C
A. nosocomialis 3 1 1 5 A, B, D
Unclassified Acinetobacter species 1 2 3 A, B
Othersb 2 1 2 1 6 A, E
Total 8 8 11 12 6 3 48
aThe non-ST119 isolates include ST63, ST64, ST93 and ST121.
bOther strains include A. baumannii, A. guillouiae, genomic species 15TU, genomic species 16, A. junii and A. ursingii.
cHospitals where each species was identified.
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this study. This finding is consistent with previous reports
[7,26]. Among the non-A. baumannii Acinetobacter species,
two ISAba3 genes flanked the blaOXA-58-like gene, which is
widely disseminated in Eastern Asian countries.
Notably, there was one major limitation of this study. We
screened the Acinetobacter isolates harbouring MBL genes
collected between 2001 and 2006 and could not directly
determine whether the MBL genes described in this study
10
0
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10
0
90807060504030
10
0
90807060504030
10
0
90807060504030
ST ID Year Hospital Specimen MBL  
genes
CHDL 
genes
121 A16 2004 A Swab* IMP-19 -
121 A2 2001 A Urine IMP-19 -
93 B15 2004 B Unknown IMP-1 OXA-58
64 B2 2001 B Blood IMP-19 -
63 A3 2001 A Urine IMP-19 -
63 A4 2001 A Urine IMP-19 -
63 A17 2005 A Swab* IMP-11 OXA-58
119 E4 2005 E Urine IMP-19 -
119 E5 2005 E Urine IMP-19 -
119 E6 2005 E Bile IMP-19 -
119 E1 2004 E Swab* IMP-19 -
119 D1 2003 D Unknown IMP-19 -
119 A11 2004 A Wound IMP-19 -
119 B7 2002 B Urine IMP-19 -
119 B9 2003 B Blood IMP-19 -
119 B16 2004 B Unknown IMP-19 -
119 B13 2003 B Urine IMP-19 -
119 B14 2003 B Urine IMP-19 -
119 A18 2006 A Sputum IMP-19 -
119 E3 2004 E Urine IMP-19 -
119 B12 2003 B Urine IMP-19 -
119 E2 2004 E Sputum IMP-19 -
- B10 2003 B Urine IMP-19 -
- B11 2003 B Urine IMP-19 -
- B4 2001 B Urine IMP-19 -
- B17 2004 B Unknown IMP-19 -
- A8 2002 A Urine IMP-19 -
- B5 2002 B Urine IMP-19 -
- B6 2002 B Blood IMP-19 -
- C1 2003 C Unknown IMP-19 -
- A10 2003 A Sputum IMP-19 -
68 B3 2001 B Sputum IMP-19 -
68 B8 2002 B Urine IMP-19 -
71 B1 2001 B Swab* IMP-19 -
71 D2 2003 D Unknown IMP-19 -
71 A1 2001 A Wound IMP-19 -
- B18 2005 B Unknown IMP-11 OXA-58
- B19 2005 B Unknown IMP-11 OXA-58
- A6 2002 A Sputum IMP-1 -
119 E8 2006 E Sputum IMP-19 -
119 A15 2004 A Sputum IMP-19 -
119 A14 2004 A Wound IMP-19 -
(a)
(b)
(c)
(d)
FIG. 3. The results of the PFGE analysis with ApaI, MLST, and the profiles of carbapenemase-encoding genes. The results shown in panel (a)
were obtained from 25 A. pittii isolates, the results in panel (b) were obtained from nine A. bereziniae isolates, the results in panel (c) were
obtained from five A. nosocomialis isolates, and the results shown in panel (d) were obtained from three unclassified Acinetobacter species isolates.
The STs were based on a Pasteur Institute scheme. The MLST was performed using only the A. calcoaceticus-A. baumannii complex. The MBL
genes and CHDL gene columns indicate the types of carbapenemase-encoding genes harboured. *Swab: nasopharyngeal swab. ST, sequence type;
MBL, metallo-b-lactamase; CHDL, carbapenem-hydrolysing class D b-lactamase.
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were still disseminated among Acinetobacter species. From
2007 to 2010, 10 Acinetobacter isolates harboured exactly the
same class 1 integron containing blaIMP-19 as identified in our
institute [10]. These data suggest the possibility of continued
integron-borne MBL gene dissemination among the species
in this region.
In conclusion, this is the first report that demonstrates
the regional and molecular epidemiology of Acinetobacter spe-
cies harbouring integron-borne MBL genes and provides
details of their species-level identification. The IMP-type MBL
genes were detected in various Acinetobacter species. In par-
ticular, the blaIMP-19 gene was predominantly identified among
many Acinetobacter species, particularly A. pittii ST119. The
CHDL genes were indeed major contributors to carbape-
nem-non-susceptibility worldwide; however, the continued
investigation of MBL genes in Acinetobacter species is
required.
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TABLE 2. Susceptibilities of Acinetobacter species harbouring MBL genes and the distribution of MBL genes among these
species
No. (%) of isolates:
A. pittii (ST119) A. pittii (non-ST119a) A. berezinae A. nosocomialis Unclassified Acinetobacter species Othersb Total
n = 18 n = 7 n = 9 n = 5 n = 3 n = 6 n = 48
Antimicrobial susceptibility
Ampicillin-sulbactam 17 (94.4) 6 (85.7) 7 (77.8) 1 (20.0) 2 (66.7) 5 (83.3) 38 (79.2)
Piperacillin 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (33.3) 2 (4.2)
Piperacillin-tazobactam 9 (50.0) 3 (42.9) 1 (11.1) 0 (0) 1 (33.3) 3 (50.0) 17 (35.4)
Ceftazidime 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Cefepime 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Imipenem 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Meropenem 3 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 1 (16.7) 4 (8.3)
Gentamicin 14 (77.8) 1 (14.3) 6 (66.7) 1 (20.0) 3 (100) 3 (50.0) 28 (58.3)
Tobramycin 15 (83.3) 1 (14.3) 6 (66.7) 1 (20.0) 2 (66.7) 1 (16.7) 26 (54.2)
Amikacin 17 (94.4) 4 (57.1) 5 (55.6) 1 (20.0) 3 (100) 3 (50.0) 33 (68.8)
Ciprofloxacin 6 (33.3) 2 (28.6) 7 (77.8) 5 (100) 1 (33.3) 5 (83.3) 26 (54.2)
Levofloxacin 16 (88.9) 3 (42.9) 7 (77.8) 4 (80.0) 2 (66.7) 4 (66.7) 36 (75.0)
Minocycline 17 (94.4) 7 (100) 9 (100) 4 (80.0) 3 (100) 6 (100) 46 (95.8)
Trimethoprim-sulfamethoxazole 0 (0) 1 (14.3) 0 (0) 0 (0) 0 (0) 1 (16.7) 2 (4.2)
Colistin 17 (94.4) 7 (100) 6 (66.7) 3 (60.0) 0 (0) 6 (100) 39 (81.3)
MBL genes
blaIMP-1 1 1 2 4
blaIMP-11 1 2 3
blaIMP-19 18 5 9 5 4 41
aThe non-ST119 isolates include ST63, ST64, ST93 and ST121.
bOther strains include A. baumannii, A. guillouiae, genomic species 15TU, genomic species 16, A. junii and A. ursingii.
CMI Yamamoto et al. IMP-type MBL genes among Acinetobacter Species 735
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 729–736
References
1. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter bau-
mannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:
826–836.
2. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emer-
gence and widespread dissemination of OXA-23, -24/40 and -58 car-
bapenemases among Acinetobacter spp. in Asia-Pacific nations: report
from the SENTRY Surveillance Program. J Antimicrob Chemother 2009;
63: 55–59.
3. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of
carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother
2010; 65: 233–238.
4. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-b-lactamases: a
last frontier for b-lactams?. Lancet Infect Dis 2011; 11: 381–393.
5. Lee K, Kim CK, Hong SG et al. Characteristics of clinical isolates of
Acinetobacter genomospecies 10 carrying two different metallo-beta-
lactamases. Int J Antimicrob Agents 2010; 36: 259–263.
6. Lin YC, Sheng WH, Chen YC, Chang SC, Hsia KC, Li SY. Differences
in carbapenem resistance genes among Acinetobacter baumannii, Acinet-
obacter genospecies 3 and Acinetobacter genospecies 13TU in Taiwan.
Int J Antimicrob Agents 2010; 35: 439–443.
7. Lee YT, Huang LY, Chiang DH et al. Differences in phenotypic and
genotypic characteristics among imipenem-non-susceptible Acinetobac-
ter isolates belonging to different genomic species in Taiwan. Int J An-
timicrob Agents 2009; 34: 580–584.
8. Figueiredo S, Poirel L, Papa A, Koulourida V, Nordmann P. First iden-
tification of VIM-4 metallo-beta-lactamase in Acinetobacter spp. Clin
Microbiol Infect 2008; 14: 289–290.
9. Chu YW, Afzal-Shah M, Houang ET et al. IMP-4, a novel metallo-
beta-lactamase from nosocomial Acinetobacter spp. collected in Hong
Kong between 1994 and 1998. Antimicrob Agents Chemother 2001; 45:
710–714.
10. Yamamoto M, Nagao M, Matsumura Y et al. Interspecies dissemina-
tion of a novel class 1 integron carrying blaIMP-19 among Acinetobacter
species in Japan. J Antimicrob Chemother 2011; 66: 2480–2483.
11. Arakawa Y, Shibata N, Shibayama K et al. Convenient test for screen-
ing metallo-beta-lactamase-producing gram-negative bacteria by using
thiol compounds. J Clin Microbiol 2000; 38: 40–43.
12. La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB
gene and flanking spacers for molecular identification of Acinetobacter
species. J Clin Microbiol 2006; 44: 827–832.
13. Karah N, Haldorsen B, Hegstad K et al. Species identification and
molecular characterization of Acinetobacter spp. blood culture isolates
from Norway. J Antimicrob Chemother 2011; 66: 738–744.
14. Chang HC, Wei YF, Dijkshoorn L, Vaneechoutte M, Tang CT, Chang
TC. Species-level identification of isolates of the Acinetobacter calco-
aceticus-Acinetobacter baumannii complex by sequence analysis of the
16S-23S rRNA gene spacer region. J Clin Microbiol 2005; 43: 1632–
1639.
15. Seifert H, Dolzani L, Bressan R et al. Standardization and interlabora-
tory reproducibility assessment of pulsed-field gel electrophoresis-
generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005;
43: 4328–4335.
16. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The popula-
tion structure of Acinetobacter baumannii: expanding multiresistant
clones from an ancestral susceptible genetic pool. PLoS ONE 2010; 5:
e10034.
17. Clinical and Laboratory Standards Institute (2012) Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically.
Approved standard, 9th edn. Document M07-A9. Wayne, PA, USA:
CLSI.
18. Clinical and Laboratory Standards Institute (2012) Performance stan-
dards for antimicrobial susceptibility testing; Twenty-Second Informational
Supplement M100-S22. Wayne, PA, USA: CLSI.
19. Levesque C, Piche L, Larose C, Roy PH. PCR mapping of integrons
reveals several novel combinations of resistance genes. Antimicrob
Agents Chemother 1995; 39: 185–191.
20. Poirel L, Nordmann P. Genetic structures at the origin of acquisition
and expression of the carbapenem-hydrolyzing oxacillinase gene
blaOXA-58 in Acinetobacter baumannii. Antimicrob Agents Chemother
2006; 50: 1442–1448.
21. Nemec A, Krizova L, Maixnerova M et al. Genotypic and phenotypic
characterization of the Acinetobacter calcoaceticus-Acinetobacter bau-
mannii complex with the proposal of Acinetobacter pittii sp. nov. (for-
merly Acinetobacter genomic species 3) and Acinetobacter
nosocomialis sp. nov. (formerly Acinetobacter genomic species
13TU). Res Microbiol 2011; 162: 393–404.
22. Nemec A, Musilek M, Sedo O et al. Acinetobacter bereziniae sp. nov.
and Acinetobacter guillouiae sp. nov., to accommodate Acinetobacter
genomic species 10 and 11, respectively. Int J Syst Evol Microbiol 2010;
60: 896–903.
23. Nemec A, Musilek M, Maixnerova M et al. Acinetobacter beijerinckii sp.
nov. and Acinetobacter gyllenbergii sp. nov., haemolytic organisms iso-
lated from humans. Int J Syst Evol Microbiol 2009; 59: 118–124.
24. Adams-Haduch JM, Onuoha EO, Bogdanovich T et al. Molecular epi-
demiology of carbapenem-nonsusceptible Acinetobacter baumannii in
the United States. J Clin Microbiol 2011; 49: 3849–3854.
25. Endo S, Yano H, Hirakata Y et al. Molecular epidemiology of carbape-
nem-non-susceptible Acinetobacter baumannii in Japan. J Antimicrob Che-
mother 2012; 67: 1623–1626.
26. Wang H, Guo P, Sun H et al. Molecular epidemiology of clinical iso-
lates of carbapenem-resistant Acinetobacter spp. from Chinese hospi-
tals. Antimicrob Agents Chemother 2007; 51: 4022–4028.
736 Clinical Microbiology and Infection, Volume 19 Number 8, August 2013 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 729–736
